2025. Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s599. DOI:https://doi.org/10.25251/y4a30r91.